In response to the FDA approval of ibrutinib + obinutuzumab as an option for treatment naïve patients with CLL/SLL based on the data from iLLUMINATE study, the panel voted on the addition of this regimen for CLL/SLL without del(17p)/TP53 mutation for frail patients with significant comorbidity and patients ≥65 y and younger patients with significant comorbidities.


In the absence of data from randomized clinical trial that has compared ibrutinib vs ibrutinib + obinutuzumab, the panel consensus was to include ibrutinib + obinutuzumab as a first-line therapy for CLL/SLL without del(17p)/TP53 mutation for frail patients with significant comorbidity and patients age ≥65 y and younger patients with significant comorbidities with a category 2B recommendation, other recommended regimen.

In the absence of data from randomized clinical trial that has compared ibrutinib vs ibrutinib + rituximab, the panel consensus was to include ibrutinib + rituximab as a first-line therapy for CLL/SLL without del(17p)/TP53 mutation for patients <65 y without significant comorbidities with a category 2B recommendation, other recommended regimen.